Oncocyte Corp 10-K Cybersecurity GRC - 2024-04-15

Page last updated on April 16, 2024

Oncocyte Corp reported their cybersecurity risk management and governance process in a yearly 10-K filed on 2024-04-15 21:55:32 EDT.

Filings

10-K filed on 2024-04-15

Oncocyte Corp filed an 10-K at 2024-04-15 21:55:32 EDT
Accession Number: 0001493152-24-014720

Note: filing items unformatted. Drop us a note with the above URL to help us prioritize formatting it!

Item 1C. Cybersecurity.

Item 1C. Cybersecurity We develop and maintain a cyber risk management program designed to identify, assess, manage, mitigate and respond to cybersecurity threats. The program is one component of our enterprise risk management system. The technical, administrative and physical controls underlying our program are based on nationally recognized practices and standards for cybersecurity. Trusted partners are an important part of our cyber risk management program. We partner with leading cybersecurity advisors and service providers to conduct periodic risk assessments and to monitor and maintain the performance and effectiveness of security controls used in our environment. The Audit Committee of the Board of Directors (the Audit Committee ) oversees our management of enterprise risks, including cybersecurity risks. Members of the management team, including our IT director and General Counsel, brief the Audit Committee on the effectiveness of risk management efforts on at least a semi-annual basis. In addition, these risks are reviewed by the Board of Directors at least annually. Our cyber risk management program helps mitigate risks that could have a material adverse effect on our business, financial condition, results or operations, cash flows or reputation. See Risk Factors Risks Related to Our Business Operations Security breaches and other disruptions could compromise our information and expose us to liability, and could cause our business and reputation to suffer.


Company Information

NameOncocyte Corp
CIK0001642380
SIC DescriptionIn Vitro & In Vivo Diagnostic Substances
TickerOCX - Nasdaq
Website
CategoryNon-accelerated filer
Smaller reporting company
Fiscal Year EndDecember 30